Controling cell death, survival, and growth by plasma-activated solutions

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K13390
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Plasma electronics
• Research Institution: Nagoya University
• Principal Investigator: Tanaka Hiromasa 名古屋大学, 未来社会創造機構, 特任講師 (00508129)
• Co-Investigator(Renkei-kenkyūsha): ISHIKAWA KENJI 名古屋大学, プラズマナノ工学研究センター, 特任教授 (60417384)
• Research Collaborator: NAKAMURA KAE 名古屋大学, 医学研究科, 研究員 ; KANO HIROYUKI NUエコエンジニアリング株式会社, 社長
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: プラズマ医療

Outline of Final Research Achievements

We have previously developed plasma-activated medium (PAM) that is plasma-treated medium for cancer treatments. In this study, we collaborated with department of obstetrics and gynecology and department of gastrointestinal surgery, and have developed plasma-activated Ringer’s lactate solution to treat with ovarian, gastric, and pancreatic cancers which are peritoneally disseminated. In addition, we collaborated with biochemical engineering lab, and found that PAM selectively eliminates undifferentiated human induced pluripotent stem cells. Thus, plasma-activated medium have broadened the applications of plasmas in medicine.

Free Research Field

プラズマ医療科学